Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over Roche’s Vabysmo (faricimab) in a head-to-head ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...

A new study from UCLA Health shows that a cardiovascular risk score already used routinely in primary care can predict who ...

Samsung Bioepis has begun direct commercialization of Byooviz in Europe. Byooviz is a biosimilar to Lucentis’ (ranibizumab).

BENGALURU: Across Bengaluru and several other cities, ophthalmologists reported that there is a steady rise in diabetic ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis ...